BresoTEC's overall mission is to improve the quality of life and advance health outcomes for patients by being the global leader in providing effective and simple technologies for the management of sleep apnea and related health conditions, where our unique medical and engineering expertise make a difference. Its immediate mission is to simplify home sleep apnea testing, increase diagnostic accuracy and boost access to sleep apnea diagnosis, especially for underserved populations.
BresoTEC Inc. is a company spun off from UHN/TRI. Its journey began in 2008 when three scientific medical inventors Drs. Douglas Bradley, Hisham Alshaer and Geoff Fernie observed that approximately 85% of people with sleep apnea were not being diagnosed owing to lack of access to and high cost of diagnostic testing. Their aim was to address this unmet need by developing simpler, more accurate and less expensive means to diagnose sleep at home to increase access to sleep apnea diagnosis, reduce costs to the healthcare system, and advance health outcomes.
BresoTEC was founded in 2012 by UHN and MaRS Innovation, and the scientific cofounder Toronto Rehabilitation Institute (TRI), and subsequently was spun off as an independent company in 2014. Its first product, BresoDX, was a single user personal device that diagnoses sleep apnea based on acoustic analysis of breath sounds during sleep. Several patent families have been filed in Canada, the US, Europe, and China covering breath sound monitoring and analysis techniques using software algorithms, as well as industrial design for sleep apnea detection. BresoTEC is in the process of developing newer multiple use acoustic-based devices for sleep apnea diagnosis to further improve accuracy, increase access and reduce costs so that more people can realize improved health and quality of life through diagnosis and treatment of their sleep apnea.